Literature DB >> 26999501

CD1a Reactivity in Non-neoplastic Adenohypophysis.

David J Pisapia1, Marc K Rosenblum, Ehud Lavi.   

Abstract

Within the differential diagnosis of patients presenting with sellar or suprasellar lesions is Langerhans cell histiocytosis (LCH). CD1a staining is frequently used to identify the presence of an abnormal proliferation of Langerhans cells on histologic sections and contributes to the diagnosis of LCH. Here, we report that the MTB-1 monoclonal antibody against the CD1a antigen reacts to native adenohypophyseal epithelial cells. We show that immunohistochemistry for CD1a exhibits strong positivity in all autopsy and surgically resected non-neoplastic adenohypophysis tested. Thus, CD1a positivity by itself should be interpreted with caution, and we recommend the routine use of a panel of stains including CD1a, Langerin, and synaptophysin in conjunction with morphologic analysis before a diagnosis of LCH is rendered. In addition, we find that pituitary adenomas fail to stain for CD1a prompting consideration of the utility of this stain as a marker for non-neoplastic gland.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26999501      PMCID: PMC5530867          DOI: 10.1097/PAS.0000000000000644

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  CD1a: a novel biomarker for Barrett's metaplasia?

Authors:  Francesco Cappello; Francesca Rappa; Fabio Bucchieri; Giovanni Zummo
Journal:  Lancet Oncol       Date:  2003-08       Impact factor: 41.316

Review 2.  CD1a in human cancers: a new role for an old molecule.

Authors:  Brendon Coventry; Susanne Heinzel
Journal:  Trends Immunol       Date:  2004-05       Impact factor: 16.687

3.  CD1a immunopositivity could help to distinguish Barrett's metaplasia from heterotopic gastric mucosa.

Authors:  Francesco Cappello; Giovanni Zummo
Journal:  J Gastroenterol Hepatol       Date:  2005-08       Impact factor: 4.029

4.  Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders.

Authors:  Sean K Lau; Peiguo G Chu; Lawrence M Weiss
Journal:  Am J Surg Pathol       Date:  2008-04       Impact factor: 6.394

5.  Cerebral involvement in IgG4-related disease.

Authors:  Deepak Joshi; Rolf Jager; Steven Hurel; Stephen P Pereira; Gavin J Johnson; Michael Chapman; Robert Fowler; Alison Winstanley; Nicholas Losseff; George Jm Webster
Journal:  Clin Med (Lond)       Date:  2015-04       Impact factor: 2.659

Review 6.  Pituitary autoimmune disease: nuances in clinical presentation.

Authors:  A Glezer; M D Bronstein
Journal:  Endocrine       Date:  2012-03-17       Impact factor: 3.633

7.  Long-term outcome of hypothalamic pituitary tumors in Langerhans cell histiocytosis.

Authors:  Bernhard Fahrner; Helmut Prosch; Milen Minkov; Martha Krischmann; Helmut Gadner; Daniela Prayer; Nicole Grois
Journal:  Pediatr Blood Cancer       Date:  2011-12-19       Impact factor: 3.167

Review 8.  Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.

Authors:  Milen Minkov
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

9.  IgG4-related hypophysitis: a new addition to the hypophysitis spectrum.

Authors:  Paola Leporati; Melissa A Landek-Salgado; Isabella Lupi; Luca Chiovato; Patrizio Caturegli
Journal:  J Clin Endocrinol Metab       Date:  2011-05-18       Impact factor: 5.958

10.  Polyclonal T-cells express CD1a in Langerhans cell histiocytosis (LCH) lesions.

Authors:  Jennifer A West; Sharon L Olsen; Jenée M Mitchell; Ross E Priddle; Jennifer M Luke; Selma Olsson Akefeldt; Jan-Inge Henter; Christopher Turville; George Kannourakis
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.